NICE has given a provisional green light for Bayer’s blood thinner Xarelto for help patients with thrombotic events

New Drug Approvals

Xarelto gains NICE thumbs up for DVT licence

NICE has given a provisional green light for Bayer’s blood thinner Xarelto for help patients with thrombotic events

NICE IS

National Institute for Health and Care Excellence

Developing a series of national clinical guidelines to secure consistent, high quality, evidence based care for patients using the National Health Service in

April 22, 2013

 

 

READ MORE AT PHARMATIMES

http://www.pharmatimes.com/Article/13-04-22/Xarelto_gains_NICE_thumbs_up_for_DVT_licence.aspx

RIVAROXABAN

Rivaroxaban (BAY 59-7939) is an oral anticoagulant invented and manufactured by Bayer; in a number of countries it is marketed as Xarelto.In the United States, it is marketed by Janssen Pharmaceutica. It is the first available orally active direct factor Xa inhibitor. Rivaroxaban is well absorbed from the gut and maximum inhibition of factor Xa occurs four hours after a dose. The effects lasts 8–12 hours, but factor Xa activity does not return to normal within 24 hours so once-daily dosing…

View original post 238 more words

Advertisements

About luciavazine

PHARMA PROFESSIONAL, ITALY
This entry was posted in Uncategorized. Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s